Published • loading... • Updated
Eli Lilly turns to South Korean RNA editing biotech for hearing loss in deal worth $1.3B
Summary by Endpoints News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Extensive research indicates that feeling lonely is not just a mental state, but a significant risk factor for heart disease, dementia, diabetes, and even hearing loss.
Eli Lilly turns to South Korean RNA editing biotech for hearing loss in deal worth $1.3B
Eli Lilly is building out its gene therapy pipeline for hearing loss through a new deal with RNA-focused startup Rznomics. The Indianapolis drug giant and Seongnam-based biotech will work together on sensorineural hearing loss in ...
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
